Curative Biotechnology Inc Contracts & Agreements
111 Contracts & Agreements
- Business Finance (64 contracts)
- Business Operations (6)
- Human Resources (17)
- Intellectual Property (17)
- Uncategorized (7)
- Seventh Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 25, 2023)
- Seventh Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 13, 2023)
- Sixth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 9, 2023)
- Second Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)
- Third Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)
- Fourth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)
- Fifth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)
- Form of Underwriting Agreement (Filed With SEC on November 7, 2022)
- Specimen of Common Stock Certificate (Filed With SEC on November 7, 2022)
- Specimen Series A Preferred Stock (Filed With SEC on November 7, 2022)
- Specimen of Series B Preferred Stock (Filed With SEC on November 7, 2022)
- Specimen of Series C Preferred Stock (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021 (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Warrant issued to Investors in August 2021 (Filed With SEC on November 7, 2022)
- Form of Warrant issued to investors on May 21, 2021 (Filed With SEC on November 7, 2022)
- Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021 (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020 (Filed With SEC on November 7, 2022)
- Form of Consultant Warrants issued between December 2020 and January 2021 (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021 (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021 (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021 (Filed With SEC on November 7, 2022)
- 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Stock Option Grant for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Underwriter Warrant (Filed With SEC on November 7, 2022)
- Form of warrant to be issued in Underwritten Offering (Filed With SEC on November 7, 2022)
- Form of Subscription Agreement for Investor Offerings in August 2021 (Filed With SEC on November 7, 2022)
- Form of Subscription Agreement for Investor Offerings on May 21, 2021 (Filed With SEC on November 7, 2022)
- Form of Note Issued to Investors between November 2020 and January 2021 (Filed With SEC on November 7, 2022)
- Settlement Agreement dated August 9, 2021 (Filed With SEC on November 7, 2022)
- Consulting Agreement dated September 27, 2021 (Filed With SEC on November 7, 2022)
- Employment Agreement with Richard Garr dated October 1, 2020 (Filed With SEC on November 7, 2022)
- Employment Agreement with Barry Ginsberg dated October 1, 2020 (Filed With SEC on November 7, 2022)
- Employment Agreement with Paul Michaels dated October 1, 2020 (Filed With SEC on November 7, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on November 7, 2022)
- Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc (Filed With SEC on November 7, 2022)
- Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on November 7, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)
- Securities Purchase Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)
- Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on November 7, 2022)
- Security Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)
- Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)
- Warrant for March 2022 Offering (Filed With SEC on November 7, 2022)
- Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)
- Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on November 7, 2022)
- Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 7, 2022)
- Form of Warrant Agency Agreement (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021 (Filed With SEC on September 30, 2022)
- Form of Underwriter Agreement (Filed With SEC on September 28, 2022)
- Settlement Agreement dated August 9, 2021 (Filed With SEC on September 9, 2022)
- Consulting Agreement dated September 27, 2021 (Filed With SEC on September 9, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on September 9, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)
- Securities Purchase Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)
- Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on September 9, 2022)
- Security Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)
- Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)
- Warrant for March 2022 Offering (Filed With SEC on September 9, 2022)
- Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)
- Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on September 9, 2022)
- Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on September 1, 2022)
- Underwriter Agreement (Filed With SEC on August 1, 2022)
- Form of Common Stock Purchase Warrant issued in Aegis Capital Underwritten Offering (Filed With SEC on August 1, 2022)
- Form of Warrant Agent Agreement between Curative Biotechnology and Issuer Direct Corporation (Filed With SEC on August 1, 2022)
- Form of Underwriter Warrant (Filed With SEC on August 1, 2022)
- Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on April 25, 2022)
- Specimen of Common Stock Certificate (Filed With SEC on April 15, 2022)
- Specimen Series A Preferred Stock (Filed With SEC on April 15, 2022)
- Specimen of Series B Preferred Stock (Filed With SEC on April 15, 2022)
- Specimen of Series C Preferred Stock (Filed With SEC on April 15, 2022)
- Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021 (Filed With SEC on April 15, 2022)
- Form of Common Stock Purchase Warrant issued to Investors in August 2021 (Filed With SEC on April 15, 2022)
- Form of Warrant issued to investors on May 21, 2021 (Filed With SEC on April 15, 2022)
- Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021 (Filed With SEC on April 15, 2022)
- Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020 (Filed With SEC on April 15, 2022)
- Form of Consultant Warrants issued between December 2020 and January 2021 (Filed With SEC on April 15, 2022)
- Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021 (Filed With SEC on April 15, 2022)
- Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021 (Filed With SEC on April 15, 2022)
- 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)
- Form of Stock Option Grant for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)
- Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)
- Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)
- Form of Subscription Agreement for Investor Offerings in August 2021 (Filed With SEC on April 15, 2022)
- Form of Subscription Agreement for Investor Offerings on May 21, 2021 (Filed With SEC on April 15, 2022)
- Form of Note Issued to Investors between November 2020 and January 2021 (Filed With SEC on April 15, 2022)
- Settlement Agreement dated August 9, 2021 (Filed With SEC on April 15, 2022)
- Consulting Agreement dated September 27, 2021 (Filed With SEC on April 15, 2022)
- Employment Agreement with Richard Garr dated October 1, 2020 (Filed With SEC on April 15, 2022)
- Employment Agreement with Barry Ginsberg dated October 1, 2020 (Filed With SEC on April 15, 2022)
- Employment Agreement with Paul Michaels dated October 1, 2020 (Filed With SEC on April 15, 2022)
- License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on April 15, 2022)
- Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc (Filed With SEC on April 15, 2022)
- Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on April 15, 2022)
- Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)
- License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)
- First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)
- Form of Securities Purchase Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)
- Form of Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on April 15, 2022)
- Form of Security Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)
- Form of Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)
- Form of Warrant for March 2022 Offering (Filed With SEC on April 15, 2022)
- Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)
- Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on April 15, 2022)